Patents by Inventor Véronique Braud

Véronique Braud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LLT-1 antibodies with new functional properties
    Patent number: 9376496
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 28, 2016
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
  • LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES
    Publication number: 20160024215
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 28, 2016
    Inventors: Petrus Johannes Louis SPEE, Peter Andreas Nicolai Reumert WAGTMANN, Stefan ZAHN, Elisabeth D. GALSGAARD, Birgitte FRIEDRICHSEN, Véronique BRAUD
  • LLT-1 antibodies with new functional properties
    Patent number: 9127052
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: September 8, 2015
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
  • LLT-1 ANTIBODIES WITH NEW FUNCTIONAL PROPERTIES
    Publication number: 20130164299
    Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
    Type: Application
    Filed: June 28, 2011
    Publication date: June 27, 2013
    Applicant: C.N.R.S.
    Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud